tbuckley/cabot-search huggingface dataset:
Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction
Authors: Michael G. White, James A.M. Shaw, Roy Taylor
Journal: Diabetes Care (2016)

The reversible nature of early type 2 diabetes has been demonstrated in in vivo human studies. Recent in vivo and in vitro studies of β-cell biology have established that the β-cell loses differentiated characteristics, including glucose-mediated insulin secretion, under metabolic stress. Critically, the β-cell dedifferentiation produced by long-term excess nutrient supply is reversible. Weight loss in humans permits restoration of first-phase insulin secretion associated with the return to normal of the elevated intrapancreatic triglyceride content. However, in type 2 diabetes of duration greater than 10 years, the cellular changes appear to pass a point of no return. This review summarizes the evidence that early type 2 diabetes can be regarded as a reversible β-cell response to chronic positive calorie balance.
Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT)
Authors: Luigi Gugliotta, Cristina Papayannidis, Andrea Piccin, Alessia Tieghi, Nicola Vianelli, Potito Rosario Scalzulli, Anna Candoni, Alfredo Dragani, Andrea Patriarca, Monia Lunghi, Rosanna Ciancia, Vincenzo Martinelli, Anna Marina Liberati, Giorgina Specchia, Annalisa Imovilli, Alessandro M. Vannucchi, Rosa Di Gaetano, Maria Luigia Randi, Francesco Passamonti, Fausto Palmieri, Maria Gabriella Mazzucconi, Lucia Mastrullo, Giuseppe Cimino, Ivana Pierri, Emma Cacciola, Alessandro Lucchesi, Annalisa Luraschi, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2010)
GW26-e5440 Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease
Authors: Ying Shen, Zhenkun Yang, Weifeng Shen, Hua Meng, Ruiyan Zhang, Qi Zhang, Lin Lu
Journal: Journal of the American College of Cardiology (2015)
GW26-e4768 Improved Recovery After Myocardial Ischemic Infarction by Copper Supplementation
Authors: Pengfei Han, Xiang Zhou, Wenjing Zhang, Qipu Feng, Ying Xiao, Xiaorong Sun, Xinmei Zhao, Haiying Fu, Y. James Kang
Journal: Journal of the American College of Cardiology (2015)
Overexpression of the Metabolic Stress Sensor and Proglycolytic Transcription Factor ΜLΧΙΡ Mediates Malignancy of Common Acute Lymphoblastic Leukemia in Vivo and Is Targetable By Allorestricted Peptide Specific T Cells
Authors: Alexandra Sipol, Thomas Grünewald, Guenther Richter, Caroline Wernicke, Hans-Jochem Kolb, Torsten Haferlach, Stefan Burdach
Journal: Blood (2014)
Trends in the Incidence of Parkinson Disease
Authors: Sirwan K. L. Darweesh, Peter J. Koudstaal, M. Arfan Ikram
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
GW26-e0726 Statin-induced Reduction of Plaque Vulnerability is Attenuated in Poorly Controlled Diabetic Patients with Coronary Atherosclerosis Disease: Serial Optical Coherence Tomography Analysis
Authors: Nana Dong, Jinwei Tian, Zulong Xie, Jiannan Dai, Meng Sun, Jingbo Hou, Yu Bo
Journal: Journal of the American College of Cardiology (2015)
Dietary fat guidelines have no evidence base: where next for public health nutritional advice?
Authors: Zoë Harcombe
Journal: British Journal of Sports Medicine (2016)

National dietary guidelines were introduced in 1977 and 1983, by the US and UK governments, with the aim of reducing coronary heart disease (CHD) mortality. The 2 specific dietary fat recommendations were to reduce total fat and saturated fat consumption to 30% and 10% of total energy intake, respectively.4 systematic reviews (3 with meta-analysis) were undertaken to examine the evidence for these dietary fat guidelines: (1) randomised controlled trial (RCT) and (2) prospective cohort (PC) evidence at the time the guidelines were introduced; and (3) RCT and (4) PC evidence currently available. This narrative review examines all evidence collated.The RCT and PC evidence available to the dietary committees did not support the introduction of the dietary fat guidelines. The RCT and PC evidence currently available does not support the extant recommendations. Furthermore, the quality of the evidence is so poor that it could not be relied on had it provided support.Dietary fat guidelines have prevailed for almost 40 years. The evidence base at the time of their introduction has been examined for the first time and found lacking. Evidence currently available provides no additional support. Public health opinion differed when the guidelines were introduced. Opposition to the guidelines is becoming more strident. Substantial increases in diet-related illness over the past four decades, particularly obesity and type 2 diabetes, indicate that a review of dietary advice is warranted.
Birinapant (TL32711), a Small Molecule Smac Mimetic, Induces Regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts That Express TNFα and Synergizes with TNFα in Vitro – A Report From the Pediatric Preclinical Testing Program (PPTP)
Authors: Malcolm A. Smith, Hernan Carol, Kathryn Evans, Jennifer Richmond, Min Kang, C. Patrick Reynolds, Srinivas Chunduru, Martin A. Graham, Brian Geier, Raushan Kurmasheva, Peter J. Houghton, Richard B. Lock
Journal: Blood (2012)
Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study
Authors: Klaus H. Metzeler, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Heiko Becker, John Curfman, Kelsi B. Holland, Sebastian Schwind, Susan P. Whitman, Yue-Zhong Wu, William Blum, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield
Journal: Blood (2010)
A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC).
Authors: Anasuya Gunturi, Sandra Aung, David F. McDermott, Elizabeth Iannotti Buchbinder
Journal: Journal of Clinical Oncology (2015)

3053 Background: HD IL-2 received FDA-approval for the front-line treatment for MM and mRCC based on its ability to produce durable responses in a subset of pts. Recently, agents targeting CTLA-4 (ipilimumab, ipi) and PD-1/PD-L1 (aPD-1) have been developed and tested in these settings. As more pts are treated with ICB as front-line therapy, it becomes increasingly important to understand if HD IL-2 is safe and efficacious as salvage therapy. Methods: PROCLAIM (www.proclaimregistry.com) is a IL-2 observational registry with > 40 participating sites consisting of a retrospective (n = 170, locked) and prospective cohort (n > 343, on-going). We queried this database to identify pts treated with HD IL-2 after receiving ipi or aPD-1 and report their safety and efficacy outcomes, compared to those who received HD IL-2 alone. Results: Within the database, there are 112 pts who received HD IL-2 without any prior or post ICB, 47 pts who received HD IL-2 after ipi and 4 who received HD IL-2 after aPD-1. The most common toxicities were hypotension, thrombocytopenia, and diarrhea in the HD IL-2 alone and prior ipi groups, while hypotension, nausea/vomiting, and pulmonary edema were most common in the prior aPD-1 group. In pts evaluable for AEs, 1.9% of the HD IL-2 alone group, 6.4% of the prior ipi group and none of the prior aPD-1 group developed immune-related adverse events. None of these events were grade 3/4. The ORR was 22.9% for pts treated with HD IL-2 alone, while the ORR for pts treated with HD IL-2 after ipi or aPD-1 was 17.7%. Median OS was 14 mos for HD IL-2 alone group, 16 mos for prior ipi group and 14.5 mos for prior aPD-1 group. Conclusions: Early patient data from the PROCLAIM database suggest that HD IL-2 is a safe treatment option for pts who have had progressive disease after prior ICB. Outcomes from additional pts as well as updated survival data will be reported. Further exploration through prospective studies is needed to determine the optimal sequence of these immunotherapies. Clinical trial information: NCT00686959.
Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management
Authors: Animesh Pardanani
Journal: American Journal of Hematology (2016)

Disease overview: Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extra‐cutaneous organs. Diagnosis: The major criterion is presence of multifocal clusters of morphologically abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC expression of CD25 and/or CD2, and presence of KIT D816V. Risk stratification: The 2008 World Health Organization (WHO) classification of SM has been shown to be prognostically relevant. Classification of SM patients into indolent (SM), aggressive SM (ASM), SM associated with a clonal non‐MC lineage disease (SM‐AHNMD) and mast cell leukemia (MCL) subgroups is a useful first step in establishing prognosis. Management : SM treatment is generally palliative. ISM patients have a normal life expectancy and receive symptom‐directed therapy; infrequently, cytoreductive therapy may be indicated for refractory symptoms. ASM patients have disease‐related organ dysfunction; interferon‐α (±corticosteroids) can control dermatological, hematological, gastrointestinal, skeletal and mediator‐release symptoms, but is hampered by poor tolerability. Similarly, cladribine has broad therapeutic activity, with particular utility when rapid MC debulking is indicated; the main toxicity is myelosuppression. Imatinib has a therapeutic role in the presence of an imatinib‐sensitive KIT mutation or in KIT D816‐unmutated patients. Treatment of SM‐AHNMD is governed primarily by the non‐MC neoplasm; hydroxyurea has modest utility in this setting; there is a role for allogeneic stem cell transplantation in select cases. Investigational drugs : Recent data confirms midostaurin's significant anti‐MC activity in patients with advanced SM. Am. J. Hematol. 91:1147–1159, 2016. © 2016 Wiley Periodicals, Inc.
High Dose Therapy (HDCT) with Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma in the Elderly: Feasibility of a Patient-Tailored Treatment Plan.
Authors: Maurizio Rupolo, Mariagrazia Michieli, Michele Spina, Daniele Bernardi, Massimiliano Berretta, Annalisa Giacalone, Umberto Tirelli
Journal: Blood (2004)
The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease
Authors: W. Schuyler Jones, Matthew T. Roe, Elliott M. Antman, Mark J. Pletcher, Robert A. Harrington, Russell L. Rothman, William J. Oetgen, Sunil V. Rao, Mitchell W. Krucoff, Lesley H. Curtis, Adrian F. Hernandez, Frederick A. Masoudi
Journal: Journal of the American College of Cardiology (2016)
MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukaemia MHC variation
Authors: FJ Hosking, S Leslie, A Moutsianas L Dilthey, Y Wang, SE Dobbins, E Papaemmanuil, E Sheridan, SE Kinsey, T Lightfoot, E Roman, Jae Irving, JM Allan, M Taylor, M Greaves, G McVean, RS Houlston
Journal: Blood (2011)
Abstract IA09: Non-cell autonomous regulation of senescence in cancer and cancer therapy
Authors: Andrea Alimonti
Journal: Cancer Research (2016)

Abstract Loss of the tumor suppressor gene PTEN opposes malignant transformation by triggering a cellular senescence response. This process is finely tuned by both cell-autonomous and non-cell-autonomous mechanisms that regulate the entry of tumor cells to senescence. I will discuss recent findings demonstrating that at the onset of senescence, PTEN null prostate tumors are infiltrated by a population of CD11b+Gr-1+ myeloid cells that protect a fraction of proliferating tumor cells from senescence, thus sustaining tumor growth. Mechanistically, I found that Gr-1+ cells antagonize senescence in a paracrine manner by interfering with the senescence-associated secretory phenotype (SASP) of the tumor through the secretion of interleukin-1 receptor antagonist. Therapeutically, I will present evidence that therapy-induced senescence and efficacy can be enhanced in PTEN null tumors by treatment that affect the recruitment of tumor-infiltrating CD11b+Gr-1+ myeloid cells or that reprogram the SASP. Taken together these data identify a novel non-cell-autonomous network, established by the innate immunity, that controls senescence evasion and chemoresistance in cancer. Targeting this network provides novel opportunities for cancer therapy. Citation Format: Andrea Alimonti. Non-cell autonomous regulation of senescence in cancer and cancer therapy. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr IA09.
Micro-RNA deletion in neuroblastoma: A possible alternative mechanism of MYCN overexpression
Authors: I. Yaniv, T. Reshef-Ronen, S. Ash, Y. Goshen, M. Jeison, B. Stark, J. Nordenberg, S. Avigad
Journal: Journal of Clinical Oncology (2006)

9052 Background: Micro-RNAs (miRNAs) are small noncoding RNAs of 18 to 25 nucleotides that regulate protein expression. The biological functions of miRNAs are not yet fully understood. miRNA genes were recently found to be abnormally expressed in several types of cancer. By negatively regulating proto-oncogenes, miRNAs could act as tumor suppressors and conversely, by inhibiting tumor suppressors function as oncogenes. Neuroblastoma (NB) is the most common solid tumor in children under 5 years of age. Major adverse prognostic factors include: age over 1 year, advanced stages, adrenal primary site, MYCN amplification, diploid or tetraploid DNA content (DI), and chromosomal aberrations - including 1p deletions. We studied a possible involvement of miRNAs in neuroblastoma. Methods: The cohort consisted of 72 patients: 65% of them were above 1 year of age, 72% with advanced stages, 33% of the patients progressed. Median follow up was 60 months (ranging 1–221). Genomic DNA from 72 tumors were analyzed for the presence of 7 miRNAs located on chromosome 1p, ranging from 1p36.33 to 1p31.1 by PCR. Results: Deletion of one or more of the miRNAs was identified in 50% of the tumors.The most prevalent deletions were of two miRNAs: miR 30e located on 1p34.2 (29%) and miR 34a on 1p 36.23 (22%), accounting for 40% of the patients with a deletion of one or both of these miRs. Interestingly, miR 30e and miR 34a are known to negatively regulate the oncogene MYCN. MYCN protein expression is currently being evaluated in this cohort. Conclusions: The deletions of these miRNAs in neuroblastoma tumors suggest their involvement as tumor suppressor genes. This implies a new mechanism for the overexpression of MYCN. Discovery of the miRNAs and their targets involved in neuroblastoma has a therapeutic potential, for the development of new targeted therapies. No significant financial relationships to disclose.
IL-18 Elicited Suppressor NK Cells with Immunoregulatory Functions
Authors: Evelyn Ullrich, Magali Terme, Laetitia Aymeric, Lionel Apetoh, Nathalie Chaput, Bernhard Ryffel, Andreas Mackensen, Joachim L Schultze, Laurence Zitvogel
Journal: Blood (2008)
Plasma Coenzyme Q10 Levels and Multiple System Atrophy
Authors: Yin Xia Chao, Zhidong Zhou, Eng-King Tan
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
The Role of FDG-PET in Hodgkin Lymphoma S/P Autologous Hematopoietic Cell Transplant (HCT) as a Predictor of Outcome.
Authors: Neel B. Shah, Mohamed Farhat, Arti Lakhani, Daniel Mcfarland, Parameswaran Venugopal, Stephanie A Gregory, Jamile Shammo, John Maciejewski, Hande Tuncer, Henry C Fung
Journal: Blood (2008)
An immunochemical analysis of multidrug resistance gene product P170 glycoprotein in human breast cancer tissues
Authors: V. Michalaki, S. Gennatas, E. Karvouni, A. Kondi-Pafiti, C. Gennatas
Journal: Journal of Clinical Oncology (2009)

e22206 Background: P-glycoprotein (gp170; encoded by the MDR1 gene (also known as PGY1) is a membrane protein capable of exporting a variety of anticancer drugs from cells. MDR1/gp170 expression has been studied in breast cancer, but the prevalence of this expression and its role in breast tumour drug resistance are unclear. To offer more effective and less toxic treatment, selecting therapies requires considering the patient and the clinical and molecular characteristics of the tumour. Our primary goal was to clarify the prevalence and clinical relevance of MDR1/gp170 expression in breast cancer patients in correlation with clinocopathologic features. Methods: In this study the expression of MDR1/gp170 protein has been investigated in a series of 40 human breast carcinomas. The immunoperoxidase antigen detection protocol, was employed using anti-p170 monoclonal antibodies (MoABs), (JSB 1 Monosan). Clinicopathologic findings, grade, and molecular markers (HER2, estrogen receptor (ER)alpha, ER beta, and progesterone receptor were also analyzed. Results: MoAB JSB-1 reacted strongly with the transmembranic antigen epitope. The proportion of breast tumours expressing MDR1/gp170 was 22% in Grade 1, 71% and 45.4% in Grade2 and Grade3 Itumors. There was no correlation with hormone receptor status, lymph node status and ΕΕR-2. Conclusions: The data of MDR-1 product expression by immunohistochemistry in breast cancer might suggest that an overexpression of this protein could constitute a hallmark of potential more aggressive phenotype for this type of neoplasia and a rapid method for pre-screening tumours for a constitutive multidrug resistance in order to orientate the cancer treatment. While the functional relevance of this expression remains to be established, it seems likely that MDR1/gp170 is an independent prognostic factor in breast tumours. No significant financial relationships to disclose.
Optimization of Isolation and Further Molecular and Functional Characterization of SSEA-4+/Oct-4+/CD133+/CXCR4+/LINneg/CD45neg Very Small Embryonic-Like (VSEL) Stem Cells Isolated from Umbilical Cord Blood.
Authors: Ewa K Zuba-Surma, Magdalena Kucia, Izabela Klich, Nicholas Greco, Mary L Laughlin, Philip Paul, Mariusz Z Ratajczak, Janina Ratajczak
Journal: Blood (2008)
Longitudinal Evaluation of Work Status and Productivity After Bariatric Surgery
Authors: Rafael Alfonso-Cristancho, Wendy C. King, James E. Mitchell, Ramesh Ramanathan, Sean D. Sullivan, Steven H. Belle, David R. Flum
Journal: JAMA (2016)

Obesity is associated with sick leave, disability, and workplace injuries. 1,2Bariatric surgery is an effective treatment for patients with severe obesity. 3,4Evidence is limited regarding the relationship between bariatric surgery and work productivity.We assessed working status and productivity change in the first 3 years following surgery for severe obesity.
Neoadjuvant hormonal therapy plus brachytherapy vs. brachytherapy alone for patients with prostate cancer: A single institution retrospective study
Authors: R. Shirazi, M. V. Mishra, A. Kleimeyer, W. M. Kassing, W. L. Barrett
Journal: Journal of Clinical Oncology (2004)

4674 Background: Neoadjuvant hormonal therapy(NHT) has sometimes been used in patients with prostate cancer opting for brachytherapy. We compared the biochemical response to NHT plus prostate brachytherapy(PBT) versus PBT alone in a consecutive series of patients treated at our institution. Methods: From 1996–2000, 125 consecutive patients with adenocarcinoma of the prostate with clinical stage T1c-T2a,b; Gleason score (GS) 3–8; PSA of 1.1 - 30 were treated either with NHT plus I-125 seed implants (Group1; n=36) vs. seed implant alone (Group2; n=89). None of these patients recieved external beam radiation. The indications for hormone therapy were most often intermediate risk disease (GS 7–8 or PSA 10–30) or significant prostatic enlargement. Prescribed radiation dose was 16,000 cGy to the periphery of the prostate. NHT was a 3 or 4 month leuprolide injection before PBT. Patients were evaluated for biochemical recurrence according to the ASTRO consensus statement, and for achieving and maintaining a PSA nadir ≤1.0, ≤0.5 or ≤0.2. The mean follow up was 43 months (Group1= 43 vs. Group2= 44), with a range of 24–80 months. Results: please see the summary in table below. Conclusions: There was no significant difference appreciated in biochemical failure rate or PSA nadir between NHT plus seed implant vs. seed implant alone. The only significant difference noted between the groups was the mean initial PSA being higher in the group who received NHT. A beneficial effect of NHT in reducing the volume of disease and improving the prognosis is possible. No significant financial relationships to disclose.
GW26-e4600 Clinical effect of recombinant human brain natriuretic peptide combined with levosimendan on acute myocardial infarction complicated with heart failure
Authors: Zhenda Zheng, Cailian Cheng, Dinghui Liu, Jianrui Zheng, Zhiming Song, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2015)
Clitoral Metastasis From Advanced Cervical Carcinoma on 18F-FDG-PET/CT
Authors: Yu-Yu Lu, Chien-Hsing Lu, Hsin-Yi Wang
Journal: Clinical Nuclear Medicine (2016)

Metastatic tumors of the clitoris from cervical carcinoma are extremely rare. Here, we described a 54-year-old woman with clitoral metastasis from cervical carcinoma demonstrated on 18F-FDG PET/CT images.